NVCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. NovoCure's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.56.
NovoCure's long-term debt to total assets ratio increased from Jun. 2023 (0.51) to Jun. 2024 (0.56). It may suggest that NovoCure is progressively becoming more dependent on debt to grow their business.
The historical data trend for NovoCure's LT-Debt-to-Total-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
LT-Debt-to-Total-Asset | Get a 7-Day Free Trial | 0.34 | 0.42 | 0.51 | 0.49 | 0.52 |
NovoCure Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
LT-Debt-to-Total-Asset | Get a 7-Day Free Trial | 0.51 | 0.52 | 0.52 | 0.53 | 0.56 |
NovoCure's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
LT Debt to Total Assets (A: Dec. 2023 ) | = | Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 ) | / | Total Assets (A: Dec. 2023 ) |
= | 596.242 | / | 1146.129 | |
= | 0.52 |
NovoCure's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as
LT Debt to Total Assets (Q: Jun. 2024 ) | = | Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 ) | / | Total Assets (Q: Jun. 2024 ) |
= | 675.201 | / | 1212.17 | |
= | 0.56 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure (NAS:NVCR) LT-Debt-to-Total-Asset Explanation
LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.
Thank you for viewing the detailed overview of NovoCure's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Pritesh Shah | officer: Chief Commercial Officer | C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355 |
Michal Nath Puri | officer: Chief Human Resources Officer | BUSINESS VILLAGE D4, PARK 6/PLATZ10, ROOT V8 6039 |
Wilhelmus Cm Groenhuysen | officer: Chief Financial Officer | C/O NAVTEQ CORPORATION, 222 MERCHANDISE MART STE 900, CHICAGO IL 60654 |
Ashley Cordova | officer: Chief Financial Officer | 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355 |
Arye Barak Ben | officer: General Counsel | TOPAZ BUILDING, 4TH FLOOR, MATAM CENTER, PO BOX 15022, SH'AR HACARMEL, HAIFA L3 31905 |
Timothy J Scannell | director | 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002 |
Kristin Stafford | director | 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087 |
Frank X Leonard | officer: President, CNS Cancers US | 20 VALLEY STREAM PARKWAY,, SUITE 300, MALVERN PA 19355 |
William Patrick Burke | officer: Chief Human Resources Officer | 195 COMMERCE WAY, PORTSMOUTH NH 03801 |
Uri Weinberg | officer: Chief Innovation Officer | NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300, MALVERN PA 19355 |
Allyson J Ocean | director | 1550 LIBERTY RIDGE DRIVE, SUITE 115, WAYNE PA 19087 |
Asaf Danziger | director, officer: Chief Executive Officer | 5 NACHUM CHAT ST., TIRAT HACARMEL L3 5112302 |
Ely Benaim | officer: Chief Medical Officer | C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850 |
William F Doyle | director, 10 percent owner | |
Jeryl L Hilleman | director | C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
From GuruFocus
By Business Wire • 01-08-2024
By PRNewswire • 08-17-2023
By Business Wire • 11-10-2023
By GuruFocus Research • 08-28-2023
By Business Wire • 08-29-2023
By Business Wire • 01-09-2024
By Business Wire • 10-15-2023
By Marketwired • 08-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.